AFT hits US approval target, triggers cash

AFT hits US approval target, triggers cash
Managing director Hartley Atkinson said Maxigesic was an effective alternative for the US$700 million of IV paracetamol sold each year. (Photo: supplied).
Dan Brunskill
The United States medical regulator has accepted an application for AFT Pharmaceuticals’ patented pain relief medicine, which if approved would open up a more than US$300 million market.The US Food and Drug Administration has formally received the application for Maxigesic IV, an intravenous form of AFT’s painkiller, which was filed in August this year.Filing with the FDA triggers milestone payments worth US$3.6m under a licensing deal with US partner Hikma Pharmaceuticals. This will be recognised in the first half of the current fi...

More Markets

Nvidia earnings boost markets, NZ sharemarket closes up
Markets Market Close

Nvidia earnings boost markets, NZ sharemarket closes up

The S&P/NZX 50 Index closed up 0.84% or 112.502 points. 

Jade Software to acquire Contec Group
Markets

Jade Software to acquire Contec Group

The acquisition adds Contec’s Madcap software to Jade’s portfolio.

AFT forges ahead with China iron injectable deal
Markets

AFT forges ahead with China iron injectable deal

Oldest iron products in Aussie are booming, while new iron injectable gets China boost.

Meridian says hydro is key to energy security and affordability
Markets

Meridian says hydro is key to energy security and affordability

Meridian says it has learnt lessons from winter 2024.